Singapore, Feb. 27 -- China-based FrontierBiotechnologies Inc. has entered into an exclusive licensing agreement with GSK, a global biopharma company. Under the terms of the agreement, GSK will obtain exclusive worldwide rights to develop, manufacture, and commercialise two of Frontier Biotech's Small Interfering RNA (siRNA) pipeline products, one of which is currently at Investigational New Drug (IND) stage and the other is a preclinical candidate.

This agreement highlights the company's expertise in early-stage siRNA drug discovery and development, and marks a significant milestone in advancing its global development strategy.

Under the agreement, the company will receive $40 million upfront and up to $963 million in success-based dev...